
    
      Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of
      150 mg (in accordance with the product SmPC) per administration. One cycle of therapy will be
      defined as 28 days of treatment. The treatment will be renewed once a month depending on the
      product tolerance.

      The trial will consist of a Screening Period (Day -28 to -1), a Treatment Period (Day 1 to
      BOR), one End of Treatment Visit, one Surgery Visit and 8 Safety Follow-Up Visits after the
      last dose of Vismodegib (+/- 5 days). Day 1 of the study will be defined as the first day a
      patient receives Vismodegib.
    
  